In patients undergoing treatment for bladder cancer, statins are significantly associated with an increased risk of tumor progression

This study was published in the New England Journal of Medicine 2006 Dec 21;355(25):2705-7

 

Study title and authors:

Use of statins and outcome of BCG treatment for bladder cancer.

Hoffmann P, Roumeguère T, Schulman C, van Velthoven R.

This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/17183004

This study investigated the association between statins and bladder cancer. The study, which lasted for 46 months, analyzed the clinical outcomes of 84 patients who had received the bacille Calmette–Guérin vaccine for the treatment of non–muscle-invasive bladder cancer.

The study found:
(a) In 53% of the patients who took statins, the tumor became more aggressive, whereas this change occurred in only 18% of the patients who did not take statins.
(b) 42% of the patients in the statin group had to undergo radical cystectomy, (radical cystectomy is the removal of the entire bladder, nearby lymph nodes, part of the urethra, and nearby organs that may contain cancer cells), as compared with only 14% of the patients who did not take statins.

In patients undergoing treatment for bladder cancer, the use of statins was significantly associated with an increased risk of tumor progression and a subsequent need for radical cystectomy.